IL-13 did not alter rhinovirus load or epithelial interferon but selectively suppressed antiviral effectors and amplified secondary inflammatory pathways, revealing how T2-inflammation may worsen viral-triggered asthma exacerbations and contribute to breakthrough exacerbations despite IL-4Rα/IL-13-targeted therapy. This evidence concerns the gene IL4R and asthma.